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1. AIMS AND OBJECTIVES 
 
 
 
AIM 
 
 
To evaluate MRI down staging, pathological response and correlation of MSI status with 
Radiotherapy response in Signet Ring Cell Carcinoma Rectum. 
 
 
 
OBJECTIVE 
 
 
 
Primary Objective 
 
MRI down staging and pathological response in Signet Ring Cell Carcinoma Rectum. 
 
 
 
Secondary Objective 
 
Correlation of microsatellite instability and Radiotherapy response in Signet Ring Cell 
Carcinoma Rectum. 
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2. INTRODUCTION 
 
Worldwide, among the people diagnosed with cancer, colorectal cancer ranks third  in 
males and second in females with 1.4 million new cases and 694,000 deaths  in 2012, 
according to Global cancer statistics, 2012(2). Incidence rates are highest in Australia and 
New Zealand, Europe, and North America and the incidence rates are lowest in Africa  
and South-Central Asia(3). 
In India according to National centre for disease informatics and research,  rectal cancer 
ranks ninth among men and is uncommon among women(4) In rural areas , the incidence 
of rectal cancer is high(5).Incidence rates  of rectal cancer varies from 5.5 to 1.6/100,000 
among men and 2.8 to 0/100,000 among women. Unusually many young Indians are 
detected with rectal cancer(6). 
Signet ring cell carcinoma rectum is one of the rare subtypes of rectal cancer. It accounts 
for about 1% of all subtypes of rectal cancers(86). It is predominantly seen in younger 
age groups , is locally advanced disease at presentation and carries poor prognosis(88) 
which is stage independent(86). They are also known to have high chances of distant  
metastasis (89). 
In the evaluation of rectal cancer, magnetic resonance imaging plays a pivotal role. High 
resolution (HR) T2 weighted MRI of the pelvis helps in preoperative staging. It  
15 
 
 
helps in evaluating the extent of tumor, relationship to mesorectal fascia and involvement 
of circumferential resection margin (CRM). 
Several randomized controlled trials have shown that neoadjuvant chemo irradiation 
followed by surgery gives significantly better outcome than surgery alone. Neoadjuvant 
radiation therapy helps in increased tumor down staging and decreased rates of local 
recurrence. While there is adequate literature on radiotherapy outcomes in rectal cancer, 
however specific data on neoadjuvant chemo irradiation outcomes in signet ring cell  
carcinoma rectum is not sufficient. 
 
Microsatellites are tandemly repeated short DNA sequences throughout the genome. 
Microsatellite instability (MSI) will lead to impaired DNA mismatch repair. It occurs in 
15% of all colorectal cancers. Preliminary studies suggest that impaired DNA mismatch  
repair genes correlates with increased sensitivity to radiotherapy. 
 
Data on the response of signet ring cell carcinoma rectum to preoperative radiation 
therapy is very limited. There are few anecdotal reports of poor response of signet ring 
cell carcinoma of rectum to radiation therapy. MSI status in signet ring cell carcinoma of     
rectum may prove to be an important biomarker for radiation therapy response. 
 
Hence in view of the paucity of data on radiological and pathological response to 
radiation therapy and MSI status in signet ring cell carcinoma of rectum we planned to 
undertake this study. 
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3. REVIEW OF LITERATURE 
 
3.1 EPIDEMIOLOGY 
 
Worldwide, cancer is one of the leading causes of morbidity and mortality. There were 
approximately 14 million new cases and 8.2 million cancer related deaths in 2012. In 
men, most common sites of cancer in 2012 were lung, prostate, colorectum, stomach, and 
liver cancer and  in  women, most common sites were breast, colorectum, lung, cervix, 
and stomach cancer(1). 
Worldwide, among the people diagnosed with cancer, colorectal cancer ranks third  in 
males and second in females with 1.4 million new cases and 694,000 deaths  in 2012(2). 
Incidence rates are highest in  Australia and New Zealand, Europe, and North America  
and the incidence rates are lowest in Africa and South-Central Asia(3) 
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Worldwide incidence of colorectal cancers (ASR) 
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3.2 INDIAN SCENARIO 
 
Incidence of colorectal cancer in India is relatively low as compared to the western 
world. Rectal cancer ranks ninth among men and does not include in top ten among 
women(4)In rural areas , the incidence of rectal cancer is high(5).Incidence rates  of 
rectal cancer varies from 5.5 to 1.6/100,000 among men and 2.8 to 0/100,000 among 
women. Many young Indians were affected with rectal cancer(6). As the age increases, 
the risk of developing colorectal cancer increases.  90% are diagnosed at an age more  
Worldwide mortality rates of colorectal cancers (ASR) 
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than 50 years with the average age of diagnosis is 64 years(7).One of the most important 
finding there has been increased number of younger (mean age of 40-45 years) patients 
from West Bengal, the North Eastern states and from Bangladesh with diagnosed  
colorectal cancer(8). 
 
 
 
 
 
 
Ten leading cancers in the Indian population 
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3.3 RISK FACTORS 
1. Age: 90% occurs at 50 years or more. The chance of  developing  rectal cancer 
progressively increases after the age of 40,and sharply after the age of 50 (9).In 
our country some studies have shown that there has been an increase in young  
patients diagnosed with rectal cancer(3). 
2. Adenomatous polyps : Neoplastic polyps are precursor lesions of colorectal 
cancers(10).An adenoma  can change to malignancy in a long latency of about 10 
years (11). Detection of and removal of these polyps before it become  malignant  
can reduce the risk of invasive colorectal cancer(12). 
3. Inflammatory bowel disease: Ulcerative colitis and Crohn’s disease both increase  
the risk of developing colorectal cancer later (10) 
4. Family history of colorectal cancer or adenomatous polyps: Increased high risk 
among first-degree family members of patients diagnosed with colorectal cancer 
and adenomatous polyps. About  20-25% of colorectal cancers are found among  
the first-degree family members(13,14). 
5. Genetic syndromes: 5 to 10% of colorectal malignancies are associated with 
genetic syndromes, such as FAP, Gardner, Lynch and Turcot. 
6. Major other risk factors include physical inactivity, obesity, diet less in fruits and 
vegetables and smoking(15). Obesity can increase the risk of colorectal cancer by 
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19%. Role of lifestyle in the development of colorectal cancer remains an area of 
research. Fish consumption can lead to reduced risk of colorectal cancers and is  
is due to omega 3 and omega 6 polyunsaturated fatty acids(16). 
One study showed there was no significant risk for chewers, smokers and alcohol 
drinkers for developing colorectal cancers when compared to those without the 
habits. Cabbage eaters had 50% reduction in risk. Fresh fish eaters had a 40–70% 
reduction in risk.  Dark-green-leafy-vegetables did not have protective effect on 
development of colorectal cancers. Some nondietary risk factors are genetic 
predisposition, tobacco smoking and ulcerative colitis(17) 
 
 
3.4 ANATOMY 
. 
The terminal portion of large intestine is rectum. It extends from recto sigmoid junction 
to approximately 12 to 15 cm and ends at the level of the levator ani. The blood supply of 
the rectum comes mainly from the superior hemorrhoidal artery and supplies the 
proximal two-thirds of the rectum. The middle hemorrhoidal artery supplies the lower 
one-third of the rectum. Superior rectal vein drains into inferior mesenteric vein and from 
there into the portal circulation. Middle rectal vein drains to the internal iliac vein and 
thereafter into inferior vena cava(18). 
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SURGICAL ANATOMY OF RECTUM 
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Lymphatic drainage of upper two-thirds of the rectum is to inferior mesenteric nodes and 
then to para-aortic nodes. Lower one-third of rectum drains  superiorly along the superior 
hemorrhoidal artery and laterally along the middle hemorrhoidal artery to nodal basin 
along the internal iliac artery(19). 
 
 LYMPHATIC DRAINAGE OF RECTUM 
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Rectum is divided into upper one third (12–16 cm), middle one third(6–12cm),and lower  
third (within 6 cm) from the anal verge(20). 
Investing fascia propria envelopes the rectum, perirectal fat and plexus of blood vessels. 
The tissues surrounding the rectum bound by the fascia propria is called as the 
mesorectum. The mesorectum contains perirectal lymph nodes(18). 
 
 The location of the tumor is usually specified in terms of the distance from 
 the anal verge. The reference anatomical landmark from which the measurements are 
made, have to be clearly mentioned. Likewise, the method of measurement; per rectal 
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examination, colonoscopy, flexible endoscopy has to be mentioned. The location of the 
tumor is important in the prognosis and selection of appropriate therapy 
 
The upper third of the rectum is bordered by visceral peritoneum known as the anterior 
peritoneal reflection. The middle third is covered by the peritoneum anteriorly. The lower 
third of the rectum is extra peritoneal and is bounded by Denonvilliers fascia. . 
Posteriorly, the presacral fascia is continuous with the posterior part of the mesorectal  
fascia or Waldeneyer fascia(21). 
 
 
 
3.5 DIAGNOSTIC EVALUATION 
 
It includes a detailed history, clinical examination including a per rectal examination, 
complete blood cell counts, liver function tests, renal function test and a baseline CEA. 
Colonoscopy or barium enema to look for polyps in the large intestine and synchronous 
growths. Imaging studies include a CT or MRI of the abdomen and pelvis for accurate 
extent of the tumor and to rule out metastasis in other abdominal organs. PET CT is done 
in some cases to help in exclusion of distant metastasis. It is more useful in cases of a 
recurrent or a suspected recurrent growth (22).Endorectal Ultrasound is being the 
imaging modality of choice for accurate T staging of the growth (23). A chest radiograph 
or a CT thorax is done to rule out lung metastasis. 
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A biopsy of the growth is the most important for confirmation of histology and is done at 
the time of the Colonoscopy / sigmoidoscopy or as a guided procedure using endorectal  
ultrasound or CT scan. 
The staging of patients with rectal cancer is carried out based on the TNM staging 
based on the American Joint Committee on Cancer (AJCC)/International Union 
 Against Cancer (UICC) staging systems. 
 
 
 
 
 
STAGING (TNM) AJCC  SEVENTH EDITION (24) 
 
Primary tumour staging (T) 
Tx        : primary tumour cannot be assessed 
T0        : no evidence of primary tumour 
Tis       : carcinoma in situ 
T1        : submucosal invasion 
T2        : muscularispropria invasion 
T3         : subserosal invasion  or into  non peritonealised perirectal tissues 
     T3a       : extends <1 mm beyond muscularis propria 
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T3b      : extends 1-5 mm beyond muscularis propria 
T3c     : extends 5-15 mm beyond muscularis propria 
T3d    : extends 15 mm beyond muscularis propria 
T4      : invasion into other organs or structures and/or perforates visceral peritoneum 
T4a   : tumour penetrates to visceral peritoneum 
T4b   :  invades  to other organs or structures 
Regional lymph nodes (N) 
Nx:  regional nodes not assessed 
N0: no regional lymph nodes 
N1: metastasis in 1-3 regional (perirectal) lymph nodes 
N1a: metastasis in one regional lymph node 
N1b: metastasis in 2-3 regional lymph nodes 
N1c: tumor deposit(s) in the subserosa, mesentery, or non peritonealized pericolic or 
perirectal  tissues without regional nodal metastasis 
N2: metastasis in 4 or more regional lymph nodes 
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N2a: metastasis in 4-6 regional lymph nodes 
N2b: metastasis in 7 or more regional lymph nodes 
Metastases (M) 
Mx: cannot be assessed 
M0: no distant metastasis 
M1: distant metastasis 
M1a: metastasis confined to one organ or site 
M1b: metastases in more than one organ/site or the peritoneum 
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3.6 MANAGEMENT OF RECTAL CANCER 
Management of rectal cancer involves multidisciplinary approach. During 1980s surgery 
was the only treatment for rectal cancer and there were more than 50% local recurrence 
after surgery. Many trials have found out that post operative radiation therapy decreases 
the local recurrence and introduction of 5 fluorouracil as adjuvant chemotherapy 
decreased the distant metastasis(25,26). In 1990s , with introduction of total mesorectal 
excision(TME)  and neoadjuvant radiation therapy, further better local control was 
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achieved.TME has revolutionized the outcomes in resectable rectal cancer leading to 
significant lower local recurrence rates at 10-year follow-up(27–29). 
 
German Rectal Cancer trial proved that the local recurrence rates were lower in  pre-
operative chemo irradiation group than in the post-operative chemo irradiation 
group(p=0.006) and thus neoadjuvant chemo irradiation became the standard of 
care(30).Neoadjuvant chemo irradiation has helped in effective down staging the tumor 
and 15 to 25% pathological complete response (p CR)(31). 
 
3.7 ROLE OF MRI IN RECTAL CANCER 
 
In the evaluation of rectal cancer, magnetic resonance imaging plays a pivotal role. High 
resolution MRI helps in preoperative staging. It helps in evaluating the extent of tumor, 
relationship to mesorectal fascia and involvement of circumferential resection margin 
(CRM). MERCURY trial assessed the  accuracy of MRI to predict resection with curative 
intent and found out 92% specificity to predict  negative circumferential margin (CRM) 
(32). Follow up results after 5 years of the same study showed that CRM clear 
preoperative MRI was significant for overall survival , disease free survival and local 
recurrence.  MRI involvement of the CRM was significantly associated with distant  
metastases(33). 
Good prognostic group  identified by MERCURY trial has following features(34) 
31 
 
 
1. CRM not involved 
2. Extramural invasion not present 
3. T2 or T3a or T3b 
4. < 5mm spread from the muscularis propria 
5. intersphincteric plane is not involved 
 
Following neoadjuvant chemo irradiation, MRI pelvis is done to see the tumor 
regression grade and CRM and helps to refine treatment plans according to the response. 
Studies have shown that ,after preoperative chemo irradiation ,MRI showed down staging 
by achieving both tumor and lymph node down staging(35) . Thus post neoadjuvant 
chemo irradiation MRI can assess tumor response before surgery. But its role in 
predicting survival outcomes has not been studied. This can be achieved by applying 
principles of  histopathology evaluation and low signal intensity appearance of fibrosis in 
MRI(36). Mandard tumor response grading system to assess TRG(37). 
 
 Tumor response was graded as follows: 
 
TRG 1 - complete regression with absence of residual cancer and fibrosis extending 
through the wall ( complete response) 
TRG 2 – rare residual tumor cells scattered throughout the fibrosis (near complete 
response) 
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TRG 3 - predominant fibrosis but increase in the number of cancer cells (moderate 
response) 
TRG 4 - residual cancer cells outgrowing the fibrosis (minimal response) 
TRG 5 - absence of regressive changes (no response). 
 
Sathyakumar etal has shown that visual assessment complete response on post chemo 
irradiation diffusion weighted MRI is an important predictor of complete response(122) 
 
Based on NCCN guidelines, rectal cancer with stages T3N0 or any T with N1 or N2, the 
standard of care is  long-course chemo irradiation, followed by TME and then adjuvant  
chemotherapy(38) 
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In Europe and Scandinavia, depending upon MRI findings patients are divided based on  
risk(39,40) 
 
1) low risk (“the good”) 
 
2) intermediate risk (“the bad”) 
 
3) High risk (“the ugly”). 
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3.8 SHORT COURSE RADIOTHERAPY AND LONG COURSE 
CHEMOIRRADIATION 
Local control and low-recurrence rates can be obtained by pre-operative short course 
radiation therapy (SCRT total dose of 25 Gy in five fractions) or long-course chemo 
irradiation (LCCRT) (50.4 Gy in 28 fractions) with concurrent chemotherapy with 5 
fluoropyrimidine followed by surgery. No concurrent chemotherapy is given with short 
course radiation and surgery is done within 7 days. After long course chemo irradiation 
the surgery is done after 6 weeks to 8 weeks(30,41,42) 
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Two randomized trials compared SCRT and LCCRT. 
Polish trial took T3–T4 lesions and seen the difference in sphincter preservation rates and 
found that proportion of sphincter preservation surgery was similar. It also showed down 
staging and complete response were more in patients who received LCCRT. Local 
control and survival were not significant(41). 
 
Trans-Tasman Radiation Oncology Group took T3N0-2M0 tumors and within 12cm from 
anal verge. They randomized to SCRT or LCCRT followed by surgery after 4–6 weeks 
followed by adjuvant chemotherapy for 4 weeks. SCRT group had high local recurrence, 
but statistically not significant. Pathological complete response was more with  
LCCRT(42), 
 
NSABP R04 study showed that 5-fluoro uracil (5-FU) or capecitabine have equal effects. 
But adding concurrent Oxaliplatin and 5 FU with radiation had no increased benefits(43). 
ACCORD study also showed adding concurrent Oxaliplatin and 5 FU with radiation had 
increased toxicity(44) 
 
Targeted therapies have been used in rectal cancer. This includes VEGF inhibitor 
Bevacizumab and EGFR inhibitors, cetuximab and panitumumab.From phase I and II 
studies, it is not clear that addition of cetuximab to chemo irradiation will result in down 
staging. Phase I and II trials showed that bevacizumab can be safely combined with 
neoadjuvant chemo irradiation. It can lead to  cell killing by damaging tumor blood 
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vessels and can normalize tumor vascularity and results in increased tumor oxygenation 
and thus causing in increased radio sensitivity(45) 
 
Management of patient’s who had complete response after LCCRT is controversial.  
Some studies did wait and watch policy without immediate surgery. The first reports 
showed a 5-year disease-free survival rate of 95% and an overall survival rate of 100% in 
the case of a clinical complete remission. But  only 25% to 50% of the patients achieving 
a clinically complete response will have a true pathological complete response (46) 
 
3.9 SURGERY IN RECTAL CANCER 
Surgery is one of the main stay treatments in rectal cancer. 
3.9.1 LOCAL EXCISION 
1. Trans anal approach 
This option can be used for tumors that are  less than 8cm from the anal verge. Proximal 
tumors cannot be approached using this technique. 
2. Trans-Sphincteric (York Mason) approach 
The entire anal sphincter is divided in the midline. Used for tumors near the 
anorectal region. 
3. Posterior para sacral (Kraske) approach 
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It is used for proximal growth. Para sacral longitudinal excision from the just above the 
anus to the inferior aspect of the gluteus maximus. 
 
The entire growth has to be removed in one uninterrupted specimen, so that the 
Pathologist is able to give a better description of the margin. The above mentioned 
techniques do not help in lymph nodal sampling. Studies have shown that the incidence 
of lymph nodal metastasis in T1 lesion is 5-10%.But in T2 lesions it is 20-35%(47). This 
high rate of lymph nodal metastasis makes local excision unsuitable for T2 lesions. 
Local excision is only done for small tumors which are less than 4cm, clinically T1 or 
favorable T2 and are about 8-10 cm from anal verge. They are usually well to moderately 
differentiated mobile lesions that occupy less than 40% of the circumference. 
 
At present, local excision is recommended for small growths that are usually less than 
four centimeters, less than 8-10 cm from anal verge, clinically T1 or occasionally, 
favorable T2 lesions. They are usually well to moderately differentiated mobile 
lesions that occupy less than 40% of the circumference(48,49). 
 
Other locally advanced rectal tumors need different surgical options. 
3.9.2 LOW ANTERIOR RESECTION 
Low anterior resection (LAR) helps in sphincter sparing surgery without compromising 
local and distant control(50). LAR is done for upper third, middle third and in some 
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lower third tumors(51).The advantage of the LAR is the possibility to 
spare the sphincter and this will result in better quality of life as they do not require 
colostomy and also less post  operative complications of poor sphincter control, bowel 
urgency and frequency(52). 
 
3.9.3 ABDOMINOPERINEAL RESECTION 
Abdominoperineal resection (APR) is the gold standard surgery for distal rectal tumors. It 
requires a proctectomy and permanent colostomy. The anatomy of the pelvis, the 
proximity to the prostate or the vagina and the thin mesorectum has a considerable 
bearing of the margins achieved following surgery(53).APR is a morbid surgery than 
LAR. Patients have a poor quality of life due to permanent colostomy(54). 
 
3.9.4 TOTAL MESORECTAL EXCISION 
Local recurrence rate were 15-30% after LAR or APR. This high rate of local recurrence 
can be attributed to lateral spread to tumor is not only seen at the level of tumor but also 
all through the mesorectum. Total mesorectal excision (TME) is the sharp dissection 
along the plane to separate the visceral and the parietal layers of the endopelvic fascia. 
The   entire rectal growth and the entire mesorectum  is dissected out in one uninterrupted  
specimen(55). This surgery helps to get better margin and thus resulting in better local 
and distant control(56). Minimum of 12-15 nodes has to be dissected for complete 
pathological staging(57). TME has slightly high rates of complications like anastomotic 
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leak and delayed wound healing. It has higher rates of local control. Both open and 
laparoscopic TME has similar oncological outcomes(58). 
 
Recent surgical advances include extra levator APR, laparoscopic approaches for TME, 
ultra low LAR and robotic LAR and TME. The major disadvantage is these techniques 
are available only in few centres and the associated cost and lack of expertise(56). 
 
3.10 ADJUVANT THERAPY IN RECTAL CANCER 
Local failure rates were high after surgery alone, 25-30%(59). Adjuvant therapy is 
needed for local and distant control. 
 
Adjuvant Radiotherapy alone 
Large radiotherapy portals are needed in post operative radiotherapy. Moreover , 
regardless of the surgical techniques the main concern was the large small bowel volumes 
and hypoxic tumor bed. Studies comparing surgery alone versus surgery followed by 
radiotherapy has shown better local control, but had no disease free or overall survival 
benefit(59,60). 
 
Adjuvant chemotherapy 
Adjuvant chemotherapy alone had shown higher local failure rates, 10-15%(60). 
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Adjuvant chemo irradiation 
With the use of adjuvant chemo irradiation there was increase in disease free and overall 
survival.  However there were increased toxicity when compared to adjuvant 
chemotherapy or adjuvant radiotherapy alone(61,62). 
Adjuvant chemo irradiation versus adjuvant radiotherapy 
Adjuvant chemo irradiation has shown better local control and overall survival and 
significant decrease in distant metastasis rate(62). 
 
Neoadjuvant radiotherapy 
Neoadjuvant therapy helps in down staging the tumor and helps in better resection with 
adequate margins. It may also help in sphincter sparing approach. Preoperative 
radiotherapy helps in better local control and overall survival. Early trials used short 
course radiation therapy followed by surgery after a short interval(63). Another study 
which addressed the interval between completion of radiotherapy and surgery has shown 
that longer duration helps in significant down staging and significant pathological 
response rate(64).There  has been higher rates of complications with preoperative 
radiotherapy like bowel urgency, incontinence and faecal soiling. Preoperative 
radiotherapy followed by TME when compared to TME  alone had showed a lower local 
relapse in the pre operative radiotherapy patients(65).Metaanalysis showed preoperative 
radiotherapy was associated with lesser local relapse and better overall survival(59). 
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Preoperative chemo radiotherapy versus preoperative radiotherapy 
Studies have shown that preoperative chemo irradiation has resulted in higher 
pathological response rate and lower local relapse rate. But toxicity profile was higher. 
There was no overall survival benefit(44,66). 
In a study , after a median follow up of 11 years, it has shown a benefit towards local 
control in preoperative chemo radiotherapy arm. There was no improvement in over all 
survival(30). EORTC trial also showed similar results(66,67). 
Neoadjuvant Long Course chemo radiation (LCCRT) followed by surgery  is the standard 
of care for all locally advanced rectal cancers. 
 
Preoperative short course radiotherapy versus long course neoadjuvant chemo 
radiotherapy 
A trial had compared these two and has shown that there was higher rate of down staging 
and good pathological response following long course chemo radiotherapy. There was no 
significant difference in toxicity, overall survival and local recurrence rate(42). 
 
Preoperative versus post operative therapy 
Studies have shown that there was benefit with preoperative chemo radiotherapy in 
reducing the pelvic recurrence, increasing down staging and increase in the number of 
sphincter sparing surgeries. There was no benefit in disease free survival and overall 
survival. There was less acute toxicity with preoperative chemo radiotherapy arm(30). 
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There was another trial to evaluate pre operative short course radiotherapy versus post 
operative chemo radiotherapy. Pre operative arm had lesser number of local recurrences. 
Increased disease free survival was seen at 3 years. But there was no significant increase 
in the overall survival(68). 
 
ROLE OF CAPECITABINE 
Capecitabine is an oral fluoro pyrimidine. Thymidine phosphorylase converts 
Capecitabine into the active drug (5-FU) within tumors cells. The studies comparing 
infusional 5-FU versus Capecitabine showed the equal benefit regarding disease free and 
overall survival. The toxicity profiles were slightly different. Capecitabine had hand foot 
skin reactions and proctitis, whereas the patients on infusional 5-FU had 
myelosuppression (69) 
 
3.11 PROGNOSTIC FACTORS IN RECTAL CANCER 
Location : Distal tumors have worst prognosis than proximal tumors(70,71) 
Studies have shown that, for pT3a the cancer-related 5-year survival rates was 85.4% and 
for pT3b it is 54.1%.  So the identification of high risk  patients with an extramural tumor 
spread of 5-mm depth .of extramural tumor invasion directs the treatment.(72). 
The depth of spread beyond the muscularis propria had increased risk of involvement of 
lymph node metastasis(73). Lymph node positivity is an independent worse 
prognostic factor and is more when 4 or more lymph nodes are involved(74). 
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Positive circumferential resection margin (CRM) is a poor prognostic factor. CRM 
involvement is an indicator of advanced disease than inadequate local surgery. 40% of 
patients prone to develop distant metastases(75). 
Histology such as signet ring cell type or melanomas have a poorer prognosis(76). Poorly 
differentiated tumors are associated with poor prognosis. Lymph vascular invasion is an 
independent factor for  poorer prognosis(77,78) 
Fixed tumors have poor surgical outcomes  and this in turn  translates into poor local 
control and survival(79,80) 
Degree of tumor regression is also an important prognostic factor. The routine use of neo 
adjuvant therapy for locally advanced rectal cancer has led to the development of grading 
systems based on the extent of tumor regression. The most commonly used are Mandard 
and the Dworak systems. Increased grades of regression after neoadjuvant therapy have a 
good prognosis(81–84) 
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Prognostic value of mandard and dworak tumor regression grading in rectal cancer: 
study of a single tertiary center. Santos MD, Silva C, Rocha A, Matos E, Nogueira C, 
Lopes C - ISRN Surg (2014) 
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3.12 SIGNET RING CELL CARCINOMA RECTUM 
Signet ring cell carcinoma rectum was first  reported by Laufman and Saphir in 
1951(85).Signet ring cell carcinoma rectum is one of the rare subtypes of rectal cancer. 
It accounts for about 1% of subtypes of rectal cancers(86) More than 50% of the tumor 
cells contain intracytoplasmic mucin displacing the nucleus(87)It is seen in younger age 
groups ,locally advanced disease at presentation and poor prognosis(88).Poor outcome is 
stage independent(86). Chances of distant metastasis is high(89).  Routes of metastasis 
are peritoneal, lymphatic and haematogenous. Peritoneal metastasis is common(89,90) 
 
One of its characteristic feature is its late manifestation and majority of them are 
diagnosed at late stages(91).Delayed  diagnosis decreases the chance of  resection with 
curative intent and it can lead to local and distant metastasis(92) 
Three factors had been found out for delayed diagnosis of signet ring cell carcinoma 
rectum(93) : 
1. tumor is rare 
2. it spreads  intramucosally with sparing of rectal mucosa and  accounts for less 
symptoms 
3. mimics inflammatory processes 
 
Signet ring cell carcinoma has abundant intracytoplasmic mucin and it displaces  
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nucleus to the periphery and  looks like  signet ring. Signet cells can coexist  in mucin 
pools of mucinous adenocarcinoma(94). 
K-ras mutation prevalence and p16 and p53 expression are less with signet ring cell 
carcinoma. B-raf mutation prevalence is high. Higher prevalence of microsatellite 
instability-high is seen. When compared to other adenocarcinomas, signet ring cell 
carcinoma fall into an independent subtype(95). 
 
One of the studies done in Indian population had shown that signet ring cell carcinoma 
had better pathological complete response and better survival. So, whether the histology 
itself or its late presentation is responsible for poor prognosis is still a debatable 
question(96). 
 
Median survival is 20 months and five year survival rate is between 10% and 35%(97–
99). Some studies showed that early diagnosis is needed to improve  outcome(100). Data 
on the response to preoperative chemo irradiation  in signet ring cell carcinoma is less 
studied(101). 
 
In an Indian study, after preoperative chemo irradiation there was 56% down staging 
followed by surgery. Among those underwent surgery 65% failed locally and distally. 
This study shows that signet ring cell carcinoma is an independent poor prognostic factor 
for an inferior overall survival(102).The Korean National registry also found that signet 
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ring cell carcinoma  have higher grade and bad disease free survival(103).In a German 
study it has been shown that 65% of signet ring carcinoma were not operable(104). 
 
 
In a study done in limited population group, preoperative chemo irradiation was 
associated with significant tumor response in patients with limited lymph node disease. 
Two different histological responses were seen. Complete response (ypT0N0) or diffuse 
infiltration of residual tumor cells to bowel wall, mesorectal region and nearby pelvic 
organs. Radiobiological explanation for this two different histological response is 
unknown(101). 
 
3.13 MICOSATELLITE INSTABILITY IN RECTAL CANCER 
 
 Cellular response to Radiotherapy 
Ionizing radiation causes cell kill by double strand DNA breaks. In response to this, 
highly complex intracellular molecular pathways are activated and are called DNA 
damage response (DDR). Activated molecules can be sensors, transducers and 
effectors of DDR(105).The sensor protein include meiotic recombination 11 (MRE11) 
complex, trimer of MRE11, RAD50, and NBS1 (XRS2)(106). DDR transducers are 
ataxia telangiectasia mutated (ATM, TEL1) and ataxia telangiectasia and RAD-3 
related proteins.They send damage signal to DDR effectors resulting in cell cycle 
arrest and may result in repair of the DNA damage. 
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So cancer cells which don’t have these proteins have more chance of death from DNA 
damage produced by radiation therapy(107,108) 
There are different DNA repair mechanisms. Most important are homologous 
recombination and non-homologous end joining (NHEJ).NHEJ is the main 
mechanism by which double strand breaks due to radiation  are repaired(109). 
 
 Molecular basis of microsatellite instability 
Microsatellites are tandemly repeated short DNA sequences throughout the 
genome. Microsatellite length will be altered by single strand breaks and can result 
in DNA replication mismatch errors. DNA microsatellite mismatch repair (MMR) 
pathway is activated and it identifies the error and then substitute with correct base 
pair. Important proteins that are involved include MLH-1, MSH (MSH-2 and 
MSH-6) and PMS-2(110). If there is failure to repair these errors in tumors with 
defective MMR, this will lead to discordant lengths of microsatellite loci between 
the tumor cell genome and normal cells. Such Microsatellite instability is seen in 
or approximately 15% of colorectal cancers(111). 
 
MSI colorectal cancers are usually sporadic, that is with methylation of promoter 
region of MLH 1. There can be germ line mutation of MLH-1 and/or MSH-2, 
MSH-6 or rarely PMS-2 in hereditary non-polyposis colorectal cancer (Lynch 
syndrome). Lynch syndrome is autosomal dominant inheritance of colorectal and 
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other cancers which includes endometrial, gastric and ovarian origin and they 
present at an early age usually mid to late forties(112). 
 
MSI colorectal cancers have the following characteristics(112–114) 
1. Location is usually proximal 
2. poorly differentiated or undifferentiated tumors 
3. tumor infiltrating lymphocytes 
4. Crohn’s disease-like host response with lymphoid aggregates 
5. mucinous, signet ring or medullary type histology 
6. better prognosis, with hazards ratio for death of 0.65 
 
 Assessment of microsatellite instability status 
It can be assessed by either immunohistochemistry (IHC) or by polymerase chain 
reaction (PCR). Sensitivity of PCR is higher(115,116).MSI IHC is simpler and 
helps to find out MSI status preoperatively from colonoscopic tumor biopsies. 
 
 Microsatellite instability and Radiation sensitivity 
DNA MMR proteins are directly involved in the DNA damage response after radiation 
induced double strand breaks. Hence their deficiency may indicate sensitivity to 
radiotherapy(117). In the context of colon cancers microsatellite instability high has 
favorable prognosis. But signet ring cell itself is a poor prognostic factor. Hence it is not 
known whether MSI high signet ring cell carcinoma has a favorable outcome. In a study 
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done in signet ring cell carcinoma rectum they found one third of them are MSI high and 
had a better five year survival. However microsatellite instability status does not predict  
survival in signet ring cell carcinoma rectum(118). In a recent study it was found that 
mortality due to signet ring cell carcinoma rectum did not differ by MSI status(119). 
 
3.14 RADIOTHERAPY PORTALS IN RECTAL CANCER 
Radiotherapy field encompasses all possible areas of local recurrence. Mostly recurrences 
are seen in pelvic soft tissue, pelvic nodes, anastomotic site and perineum(120).In T4 
tumors there are chances of recurrence in anterior structures. The lymph nodal groups 
included are the internal iliac and the obturator . The external iliac lymph nodes are 
included only when anterior tumor extension or involvement of adjacent structures. 
 
Conventional radiotherapy 
Pelvic radiotherapy can be given by a four field box technique or by 3-field approach 
(Two laterals and a PA field). 
 
 Field borders 
Whole Pelvis 
1. AP-PA 
Superior:  L5-S1 to encompass the attachment of the posterior peritoneum 
52 
 
 
Lateral: 1.5 cm beyond the widest bony margins of the true pelvis to encompass the                     
possible lateral extension and the internal iliac chain. 
 
Inferior:  3-3.5cm beyond the lower extent of the tumor. It can be located either by direct 
palpation if it is a lower growth, or with the aid of rectal contrast or an endoscopically 
placed clip. 
For post operative cases, in cases of post LAR it is placed 3 cm beyond the region of the 
anastomosis, or in cases of post APE placed beyond the anal verge to encompass the 
perineal scar. 
The inguinal nodes are included only in case of extension into the anal canal or 
involvement of the anterior structures. 
The para aortic nodes are not included in the portals as it is considered to be metastatic 
disease. 
2. Lateral fields 
Anterior:   T2 and T3 lesions it is placed at the posterior margin of the pubic symphysis 
to include the internal iliac nodes. 
For T4 lesions: Usually placed at the anterior margin of the pubic symphysis to include 
the external iliac nodes. 
Posterior:  entire sacral hollow 
Superior and inferior: same as that of AP/PA fields. 
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Boost field 
Primary tumor with a 2 cm margin. The nodes are not routinely included in the boost 
field. 
Manual blocks are placed to shield the small intestine as well as the soft tissue 
posterior to the sacrum. 
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 Portals used post LAR 
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 Portals used post APE 
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Conformal radiotherapy 
Conformal radiotherapy helps in sparing the normal tissue without compromising the 
dose delivered to the target volumes. The GTV comprises of GTV-Tumor and the GTV-
Node which is seen both clinically as well as on imaging. 
The CTV includes the entire mesorectum, presacral space as well as the obturator, 
internal iliac groups. The common iliac and the external iliac are not routinely 
included in all cases. 
The PTV is the expansion of the CTV to account for organ motion and set up errors. 
The OAR’s are routinely contoured and are kept below their threshold limits. 
Guidelines in rectal IMRT(121) 
CTV Rectum: Rectal GTV +1.5 cm radially, +2.5 cm craniocaudally) 
CTV Nodes: Nodal GTV + 1.5 cm symmetrical expansion 
Uninvolved iliac vessels + 1.0 cm = CTV (include external iliac if T4) 
Presacral lymphatic CTV: contouring from mid S1-S5 and 8 mm tissue anterior to the 
anterior border of the sacral bone 
The mesorectum and perirectal lymphatics CTV : 
Posterior Border: anterior border of the sacrum and gluteus maximus 
Lateral Border: ileum, piriformis and obturator muscles 
Anterior Border: should overlap by 1 cm into the bladder, vagina or prostate 
PTV: expanding all of the above by 0.5 cm symmetrically 
IMRT reduces dose to normal tissues. It has concerns regarding dose heterogeneity and 
geographical miss as there can be differences in the position of the target 
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4. MATERIALS AND METHODS 
 
22 patients with signet ring cell carcinoma rectum who have undergone preoperative -
long course chemo irradiation therapy (LCCRT) were enrolled for this study after 
clearance from the institution review board. The standard work up of rectal cancer 
includes biopsy, MRI pelvis ,CEA ,CT thorax and abdomen or chest X ray and USG 
abdomen and pelvis is done to rule out distant metastases. Patients who are non 
metastatic were included in the study. All the biopsy proven patients had diagnostic MRI 
pelvis and MSI status assessment using immunohistochemistry before the initiation of 
radiation therapy. All patients received preoperative long course chemo radiotherapy to a 
dose of 50.4 Gy. They also receive concurrent chemotherapy with Capecitabine (825 
mg/m2) twice daily on days of radiation therapy. After 6 weeks of radiotherapy, response 
assessment was done using MRI pelvis. Patients who were operable after radiotherapy 
underwent Total Mesorectal Excision. Radiotherapy response was assessed by comparing 
pretreatment MRI with post radiation therapy MRI down staging, pathological response 
and correlation with MSI status. 
MRI PELVIS Protocol 
Standard high resolution (HR) T2 weighted MRI of the pelvis will be performed in 
sagittal, oblique axial (perpendicular to the rectum) and oblique coronal (parallel 
to the rectum) planes. Diffusion weighted (DWI) MR images will be obtained in 
the same oblique axial plane as T2 weighted high resolution images using respiratory 
triggered, single shot, echo-planar-imaging with b-values of 0, 100,and 800 sec/mm2. 
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Tumor regression grading 
In our center, we use Mandard tumor response grading system to assess TRG. 
Tumor response was graded as follows: 
TRG 1 - complete regression with absence of residual cancer and fibrosis extending 
through the wall (Complete response) 
TRG 2 – rare residual tumor cells scattered throughout the fibrosis (Near complete 
response) 
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TRG 3 - predominant fibrosis but increase in the number of cancer cells (Moderate 
response) 
TRG 4 - residual cancer cells outgrowing the fibrosis (Minimal response) 
TRG 5 - absence of regressive changes (No response). 
 
Immunohistochemistry protocol to assess MSI status 
1. Paraffin embedded tissue sections will be cut at 4μ thickness and floated 
in poly L-lysine coated slides and incubated overnight at 37˚C. 
2. These slides will be then treated with 4% milk solution for 10 minutes to 
eliminate the hydrophobic effect and give positive charge to the slides. 
3. Then the slide labels will be bar coded and the labeled slides will be 
loaded in Ventana Benchmark XT autostainer (a fully automated immunostainer). 
4. Individual protocols have been designed in the software attached to the 
machine for each marker. Specific protocols will be selected according to 
the marker. 
5. A standard protocol will be used for most of the markers with a minimal 
variation for few individual markers. The steps included in this protocol are 
as follows: 
a. Deparaffinization 
b. Liquid coverslip application. 
c. Heat induced antigen retrieval by treating with standard CC1 solution (pH patent with 
the company) for one hour at 90˚C. 
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d. Then the primary antibody will be added and incubated for 40 minutes @ 37˚C. 
e. Then the secondary antibody (Multimer) will be added and incubated for 8 minutes. 
f. Finally the slides will be counterstained with Haematoxylin and incubated for 8 
minutes, followed by incubation with the bluing reagent for 4 minutes. (From antigen 
retrieval till counterstaining, in between every step the slides were washed with reaction 
buffer. The whole process is automated). Then the slides will be brought to 80% alcohol 
(2 changes) to remove the liquid cover slip and then dried and mounted in DPX. 
 
 
Inclusion criteria: 
1. Signet ring cell carcinoma rectum 
2. Planned for neoadjuvant radiotherapy along with concurrent chemotherapy 
(Concurrent Capecitabine) 
3. No prior pelvic malignancies 
4. No history of prior radiation to the abdomen/pelvis 
5. Not a known case of myelodysplastic syndrome/myelofibrosis 
 
Exclusion criteria 
1. Metastatic disease 
2. Pregnant women 
 
62 
 
 
The proposed study was presented in the Institutional Review Board (IRB) which 
includes Research committee and Ethics Committee and approval was obtained 
(copy enclosed). The patients were selected based on the inclusion and exclusion 
criteria. 
Detailed diagrammatic Algorithm of the study 
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SIGNET RING CELL CARCINOMA RECTUM PATIENTS 
 
  
 Eligibility                                   1.SIGNET RING CELL CARCINOMA RECTUM 
                                                                                    2 NON METASTATIC  
3. PATIENTS PLANNED FOR LONG COURSE CHEMO IRRADIATION THERAPY  
 
 
 
MRI PELVIS AND MSI IMMUNOHISTOCHEMISTRY DONE BEFORE STARTING RADIATION THERAPY 
 
 
 
 
LONG COURSE CHEMO IRRADIATION 
 
                                 (50.4 Gy) 
 
 
RESPONSE ASSESSMENT AFTER 6 WEEKS USING MRI PELVIS 
 
 
 
 
 
SURGERY 
 
 
HISTOPATHOLOGY AND PATHOLOGICAL RESPONSE 
 
Sample size 
There were total of 22 patients who were included in the study during a period of 2013 to 
2016. 8 patients were prospective and 14 patients were retrospective.                                                       
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5. RESULTS 
Patient characteristics 
 
There were 13 male patients and 9 female patients. 59.1% of the patients (13 patients) 
were between 20 to 40 years. The mean age group was 38 years, ranging from 18 to 62 
years. 90.9% of them were married. All patients had ECOG performance score 1. 
 
Table 1: Patient characteristics 
 
Variables Frequency 
(n =22) 
Percentage (%) 
 
Age(years) 
 
<20years 
 
20-40years 
 
>40years 
 
Mean -38(Range 18-62 ) 
 
1 
 
13 
 
8 
 
 
 
4.5% 
 
59.1% 
 
36.4% 
Sex 
 
Male 
 
Female 
 
 
13 
 
9 
 
 
59.1% 
 
40.9% 
Marital status 
 
Married 
 
Unmarried 
 
 
20 
 
2 
 
 
90.9% 
 
9.1% 
65 
 
 
ECOG Performance score 
 
0 
1 
2 
3 
4 
5 
 
 
0 
22 
0 
0 
0 
0 
 
 
 
 
0 
100% 
0 
0 
0 
0 
 
 
Fig : 1 :  Distribution of age 
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Fig 2 : Distribution of sex 
 
 
Fig 3 : Distribution of Marital status
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Disease characteristics at the time of diagnosis 
72.7% of the tumors were located within 5 cm from anal verge. 59.1% had normal CEA 
at the time of diagnosis. 72% were T3 lesions and 63.6% had N2 disease. All the patients 
had signet ring cells. In 45.5% of patients there were mucin component also along with 
signet ring cells. 40.9% had diversion stoma before the initiation of treatment. 
 
Table 2 : Disease characteristics at diagnosis 
 
Characteristics N(22) Percentage(%) 
 
Distance from anal verge 
 
0-5cm 
 
5-10cm 
 
≥10cm 
 
 
 
16 
 
6 
 
0 
 
 
 
72.7% 
 
27.3% 
 
0 
                 CEA at diagnosis 
 
<5ng/ml 
 
≥5ng/ml 
 
 
13 
 
9 
 
 
59.1% 
 
40.9% 
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T –stage at 
diagnosis 
 
T1 
 
T2 
 
T3 
 
T4 
 
 
 
 
0 
 
2 
 
16 
 
4 
 
 
 
 
0% 
 
9.1% 
 
72.7% 
 
18.2% 
 
N – stage at diagnosis 
 
N0 
 
N1 
 
N2 
 
 
 
1 
 
7 
 
14 
 
 
 
 
4.5% 
 
31.8% 
 
63.6% 
 
HISTOLOGY 
 
Signet ring cell 
 
Signet ring + mucin 
 
 
 
 
 
12 
 
10 
 
 
 
54.5% 
 
45.5% 
 
Diversion 
 
Yes 
 
No 
 
 
9 
 
13 
 
 
40.9% 
 
59.1% 
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Figure 4 : Distance from anal verge 
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Figure 5 : T stage 
 
 
Figure 6  : N stage 
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Figure 7 :  Histology 
Figure 8 : Diversion 
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Details of chemo irradiation 
77.3% received radiation via two dimensional four field box technique. 13.6%  received 
3DCRT and 9.1% received by IMRT. Patients who underwent 2D, 3D conformal RT and 
one patient who underwent IMRT received 50.4Gy in 28 fractions (Phase 1: 45Gy in 25 
fractions and Phase II: 540cGy in  3 fractions). Second patient who underwent IMRT 
received simultaneous integrated boost of 45Gy in 25 fractions to CTV 45 and 50.4Gy in 
25 fractions to CTV 50.4. Out of 22 patients, 21 patients had concurrent Capecitabine 
(825mg/sq.m twice daily on days of radiation therapy) and one patient did not receive 
concurrent Capecitabine due his  co morbid illness. 
 
Table 3 : Details of chemo irradiation therapy 
 
Characteristics N(22) Percentage 
(%) 
 
Dose : 
 
50.4Gy in 28 fractions 
 
50.4Gy in 25 fractions (SIB) 
 
 
 
21 
 
1 
 
 
 
95.5% 
 
4.5% 
Technique 
 
2D 
 
3DCRT 
 
IMRT 
 
 
17 
 
3 
 
2 
 
 
77.3% 
 
13.6% 
 
9.1% 
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Concurrent Capecitabine 
 
Yes 
 
No 
 
 
21 
 
1 
 
 
95.5% 
 
4.5% 
 
 
 
 
 
Figure 9:  RT Technique 
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MRI Tumor regression grade 
One patient did not have post radiation therapy response assessment MRI since there was 
clinical progression. 57.1 % patients showed only minimal response in MRI after 6 weeks 
of long course radiation therapy. None of the patients had complete MRI response. 
 
 
Table 4 : MRI Tumor regression grade 
 
 
 
 
MRI TRG N=21 Percentage (%) 
 
 
 
1= Complete response 
 
2= Near complete response 
 
3= Moderate response 
 
4=Minimal response 
 
5=No response 
 
 
 
0 
 
1 
 
3 
 
12 
 
5 
 
 
 
0% 
 
4.8% 
 
14.3% 
 
57.1% 
 
23.8% 
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Figure 10 : MRI Tumor regression grade 
 
 
 
 
 
DETAILS OF SURGERY 
 
Among 22 patients seven (31.8%) were inoperable. 31.8% had Abdominoperineal 
resection and 22.7% had Anterior resection. 
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Table 5: Details of Surgery 
 
DETAILS OF SURGERY N =22 Percentage (%) 
 
Anterior Resection 
 
APE 
 
Hartmann’s Operation 
 
Exenteration 
 
Inoperable 
 
5 
 
7 
 
2 
 
1 
 
7 
 
22.7% 
 
31.8% 
 
9.1% 
 
4.5% 
 
31.8% 
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Figure 11: Details of Surgery 
 
 
 
 
 
Pathological tumor regression grade 
Among the 15 patients who underwent surgery, post operative histopathological 
examination revealed, 40% had complete response, 26.7% had near complete response 
and 26.7% had no response. 
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Table 6: Pathological tumor regression grading 
PATHOLOGICAL TRG N = 15 Percentage 
(%) 
 
1= Complete response 
 
2= Near complete response 
 
3= Moderate response 
 
4=Minimal response 
 
5=No response 
 
6 
 
4 
 
0 
 
1 
 
4 
 
 
 
40% 
 
26.7% 
 
0 
 
6.6% 
 
26.7% 
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Figure 12 : Pathological Tumor regression grade 
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5.1 CORRELATION BETWEEN MRI TRG AND PATHOLOGICAL TRG 
 
 
 
 
 
 
 
Table 7: 
Correlation between 
MRI TRG and 
Pathological TRG 
 
 
 
 
 
 
 
 
 
 
 
 
 
No of patients MRI TRG HPE TRG 
1 4 2 
2 4 4 
3 4 5 
4 4 5 
5 4 1 
6 3 1 
7 4 2 
8 4 1 
9 5 1 
10 3 5 
11 2 2 
12 4 1 
13 4 5 
14 5 1 
15 4 2 
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Figure 13: Correlation between MRI TRG and Pathological TRG 
 
 
 
MSI STATUS 
MSI Immunohistochemistry was done for 17 patients. MSI was negative for all the 17 
patients. Hence MSI status and radiotherapy response could not be correlated in Signet 
ring Cell Carcinoma Rectum. 
 
 
5.2 CHARACTERISTICS OF PATIENTS WITH COMPLETE RESPONSE 
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Patient 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
Age in years 23 46 26 26 27 32 
Sex Female Male Female Male Male Female 
Pretreatment CEA 
(ng/ml) 
< 5 <5 <5 <5 ≥5 <5 
Location from anal 
verge in cm 
5 7 8 1 3 3 
Diversion No No No Yes No No 
T stage T3 T3 T3 T2 T3 T4 
N stage N2 N2 N2 N1 N2 N2 
CRM( pre RT MRI) Involved Involved Involved Involved Involved Involved 
RT Dose in Gy 50.40 50.40 50.40 50.40 50.40 50.40 
Capecitabine Yes Yes Yes Yes Yes Yes 
RT technique 2D 3D 2D 2D 2D 3D 
Post RT CEA 
(ng/ml) 
<5 <5 <5 <5 <5 <5 
MRI TRG 4 3 4 5 4 5 
Table No: 8: Characteristics of patients with complete response  
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Among 15 patients who underwent surgery, 6 had complete pathological response. 
Median age group was 30 years.50% were males and 50% females. 67% of them had 
lower rectal tumors. 83% had normal CEA.  67% had T3 disease and 16% had T4 disease 
and 83% had N2 disease.  CRM was involved all the 6 patients. MSI was negative  for 5 
patients. All patients received long course chemo irradiation with a dose 50.40Gy in 28 
fractions with concurrent Capecitabine. Reassessment MRI done after 6 weeks showed 
that 50% had minimal response, 33.3% had no response and remaining had moderate 
response. Based on MRI findings and clinical assessment, 50% underwent anterior 
resection and 50% underwent abdominoperineal excision. Histopatholgical examination 
showed all had complete response (ypT0N0). 
 
 
Post operative margin 
Status 
Negative Negative Negative Negative Negative Negative 
MSI status Not done Negative Negative Negative Negative Negative 
Surgery AR AR AR APE APE APE 
Pathological TRG 1 1 1 1 1 1 
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6. DISCUSSION 
 
Signet ring cell carcinoma of the rectum is a rare subtype of rectal cancer in younger 
populations and is associated with poor prognosis. While the standard of care in any 
locally advanced rectal cancer is long course chemo irradiation followed by total 
mesorectal excision, the same approach does not give similar outcomes in Signet ring 
Cell Carcinoma rectum. Current literature supports the above said management of rectal 
cancer; however specific data on outcomes like down staging following neoadjuvant 
chemo irradiation in signet ring cell carcinoma rectum is lacking. There are few anecdotal 
reports of poor response seen in of signet ring cell carcinoma of rectum to radiation 
therapy. We found similar outcomes when MRI was done 6 weeks since completing long 
course chemo irradiation. However we observed an unusual and rarely reported outcome 
where 6/15 (40%) patients had shown complete pathological response. 
Most of the studies in rectal cancer showed that signet ring cell carcinoma is seen in 
younger age group. In our study also, 60% of the patients were less than 40 years, mean 
age was 38 years and predominantly seen in males. 
In our study, 72.7% of the tumors were low rectal tumors and pretreatment CEA was 
normal in 59.1%. 72% were T3 lesions and 63.6% had N2 disease. Hence majority 
patients belong to the category of “The Bad” rectal cancers and a few were “The Ugly” 
rectal cancers. 
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Elmashad etal, Sathyakumar etal showed that after preoperative chemo irradiation, a 
reassessment MRI pelvis after 6 weeks showed down staging by achieving both tumor 
and lymph node down staging in rectal cancers. In our study we did post radiation 
therapy reassessment MRI pelvis which showed 57.1 % patients had minimal response 
and 23.8% had no response. Among these 21 patients who had post radiation therapy 
MRI pelvis, 15 underwent surgery based on MRI response assessment and clinical 
examination. Though most patients had only minimal response in reassessment MRI 
pelvis, based on Surgeon’s clinical assessment, many were operable and had undergone 
surgery. Surgical pathology showed that 40% had complete response, 26.7% had near 
complete response and 26.7% had no response. This result was irrespective of the 
reassessment MRI pelvis response. Even patients who did not show any response in 
reassessment MRI, showed histopathological complete response. Hence the predictive 
role of response assessment after long course chemo irradiation with MRI in signet ring 
cell carcinoma rectum needs to be cautiously interpreted. 
Data on microsatellite instability and radiation response in signet ring cell carcinoma 
rectum is lacking. In our study MSI IHC could be done only for 17 patients and all were 
negative for MSI. Hence no correlation between MSI and radiation response could be 
inferred in this study. Kakar etal showed that about one third of signet ring cell 
carcinomas of the colorectum have microsatellite instability, however it was not a 
significant predictor of survival in signet ring cell carcinoma of the colorectum. 
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The major limitation of our study was limited cohort of this rare subtype of signet ring 
cell carcinoma rectum. Owing to time constraints we could not correlate the follow up 
data on local control and disease free survival and overall survival. In this study MSI 
status was assessed using Immunohistochemistry. PCR is considered to be more sensitive 
and specific test. However an interesting observation of this study revealed that 40% had 
complete histopathological response even though their MRI predicted poor response to 
radiation therapy. Hence the predictive role of MRI in down staging the tumor after 
radiation therapy in signet ring cell carcinoma rectum needs to be evaluated more 
extensively. Furthermore, bad biology of signet ring cell carcinoma requires a new 
paradigm which includes molecular and genetic staging, and also aggressive treatment 
strategies. 
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7. CONCLUSION 
The predictive value of MRI down staging in Signet Ring Cell Carcinoma Rectum 
following neoadjuvant long course chemo irradiation therapy is not always in 
concurrence and needs to be re evaluated. The pathological complete response rate in 
these tumors relatively matches the response rates as seen in non signet ring cell types. 
Hence long course chemo irradiation still plays a significant role in the management of 
these tumors. MSI status with IHC technique may be suboptimal and it should preferably 
be assessed using PCR techniques in future studies.  
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9. APPENDIX 
 
INFORMATION SHEET 
Christian Medical College, Vellore 
Department of Radiation therapy 
MRI DOWNSTAGING, PATHOLOGICAL RESPONSE AND 
MICROSATELLITE INSTABILITY STATUS IN PATIENT’S WITH SIGNET 
RING CELL CARCINOMA RECTUM UNDERGOING PREOPERATIVE LONG 
COURSE CHEMO IRRADIATION 
You are being requested to participate in a study which will assess the response of your 
tumor to radiation therapy and see the relationship between MSI status and radiation 
response. 
You will be undergoing treatment of your condition as per current standard practice. MRI 
pelvis will be done during initial evaluation and after 6 weeks of radiation therapy. The 
Radiologist will compare the stage between the pre and post radiation therapy MRI. If the 
tumor is operable as per opinion of Colorectal Surgeons and the MRI findings you will 
undergo the appropriate surgery 
Our Pathologist will report the pathological response to radiation therapy in the surgical 
specimen. A special test called immunohistochemistry will be done on your diagnostic 
biopsy specimen to test MSI status. 
Can you withdraw from this study after it starts? 
Your participation in this study is entirely voluntary and you are also free to decide to 
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withdraw permission to participate in this study. If you do so, this will not affect your 
treatment at this hospital in any way. 
What will happen if you develop any study related injury? 
We do not expect any injury to occur. 
Will you have to pay for the test? 
You will have to pay for MRI and treatment as it is considered the standard of care .As 
we are investigating the role of MSI in radiation response, you will not have to pay for 
MSI immunohistochemistry. 
Will my treatment details be kept confidential? 
All your treatment details will not be revealed to any third party The results will 
be reviewed only by people associated with the study. 
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but you will not be 
identified by name in any publication or presentation of results. However, your medical 
notes may be reviewed by people associated with the study, without your additional 
permission, should you decide to participate in this study. 
If you have any further questions, please ask 
Dr Rajkrishna B 
Department of Radiation Therapy 
Christian Medical College, Vellore 
Tamil Nadu, 632004 
Mobile: +919626947477, Email: rajkb111@yahoo.co.in 
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MRI DOWNSTAGING, PATHOLOGICAL RESPONSE AND 
MICROSATELLITE INSTABILITY STATUS IN PATIENT’S WITH SIGNET 
RING CELL CARCINOMA RECTUMUNDERGOING PREOPERATIVE LONG 
COURSE CHEMO IRRADIATION 
INFORMED CONSENT 
Sl. Number: 
Participant ID: Date: 
Participant name: Hospital Number: 
I Mr / Mrs …………………………………………………, Son/Daughter 
of………………………………….. Hospital number ……………………………… have 
been 
explained in a language that I clearly understand about the nature of the condition and its 
associated prognosis. The options, the benefits of the proposed line of standard treatment 
and the side effects have been clearly explained to me. The costs associated with 
treatment have also been mentioned. 
I have understood that my clinical,radiological and pathological information will be used 
for research purpose. The aim, the methods of collection and usage of the data, the 
proposed end points have been clearly explained to me by Dr. Rajkrishna B 
I am aware that the data collected from my participation in this study, will be utilized for 
correlating radiotherapy response. 
I am aware that my participation in this study is entirely voluntary. 
I am also aware that I may, at any time of the study, seek more information regarding the 
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same. I may wish to withdraw from the study at any point, after suitable intimation, for 
reasons that I may not be willing to share. 
I hereby give my informed consent for participation in the study. My consent has 
been given under my own free will and under no undue or external coercion. 
PARTICIPANT                                                                           WITNESS 
NAME IN CAPITALS:                                                               NAME IN CAPITALS: 
SIGNATURE:                                                                              SIGNATURE: 
THUMB IMPRESSION:                                                              THUMB IMPRESSION: 
PLACE:                                                                                          PLACE: 
ADDRESS                                                                                      ADDRESS 
CONTACT NUMBER:                                                                   CONTACT NUMBER: 
DATE AND TIME:                                                                          DATE AND TIME: 
 
 
INVESTIGATOR’S NAME AND SIGNATURE 
DATE  
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No Age SEX Marital statusOCCUPATIONNATIONALITYECOG Distance from anal verge in cmPretre tm nt CEADiversion BIOPSY MSI MLH1 MSH6 MSH2  PRE RT STAGET STAGE N STAGE
1 62 MALE MARRIED SKILLED NON INDIAN 1 4 26.2 YES SIGNET + MUCINNEGATIVE POSITIVE POSITIVE POSITIVE T3bN1 T3 N1
2 48 FEMALE MARRIED UNSKILLEDINDIAN 1 0 2.57 YES SIGNET + MUCINNEGATIVE POSITIVE POSITIVE POSITIVE T3bN1 T3 N1
3 32 MALE MARRIED UNSKILLEDINDIAN 1 0.5 4.53 YES SIGNET + MUCINNOT ASSESSED. . . T3bN2 T3 N2
4 44 MALE MARRIED SKILLED INDIAN 1 5 5.87 YES SIGNET RING CELL CARCINOMANEGATIVE POSITIVE POSITIVE POSITIVE T4aN2 T4 N2
5 57 MALE MARRIED SKILLED INDIAN 1 6 8.43 NO SIGNET + MUCINNEGATIVE POSITIVE POSITIVE POSITIVE T2N1 T2 N1
6 33 FEMALE MARRIED UNSKILLEDNON INDIAN 1 8 4.94 YES SIGNET RING CELL CARCINOMANEGATIVE POSITIVE POSITIVE POSITIVE T4aN2 T4 N2
7 62 MALE MARRIED UNSKILLEDINDIAN 1 7 2.78 NO SIGNET RING CELL CARCINOMANOT ASSESSED. . . T4aN1 T4 N1
8 22 FEMALE MARRIED UNSKILLEDNON INDIAN 1 3 2.04 NO SIGNET RING CELL CARCINOMANEGATIVE POSITIVE POSITIVE POSITIVE T3dN2 T3 N2
9 23 FEMALE MARRIED UNSKILLEDINDIAN 1 5 2.17 NO SIGNET + MUCINNOT ASSESSED. . . T3N2 T3 N2
10 46 MALE MARRIED UNSKILLEDINDIAN 1 7 2.79 NO SIGNET + MUCINNEGATIVE POSITIVE POSITIVE POSITIVE T3N2 T3 N2
11 38 FEMALE MARRIED SKILLED INDIAN 1 5 0.797 NO SIGNET RING CELL CARCINOMANEGATIVE POSITIVE POSITIVE POSITIVE T3cN2 T3 N2
12 39 FEMALE MARRIED SKILLED INDIAN 1 3 18.1 NO SIGNET + MUCINNEGATIVE POSITIVE POSITIVE POSITIVE T3cN2 T3 N2
13 26 FEMALE MARRIED UNSKILLEDINDIAN 1 8 0.57 NO SIGNET RING CELL CARCINOMANEGATIVE POSITIVE POSITIVE POSITIVE T3cN2 T3 N2
14 26 MALE UNMARRIEDUNSKILLEDNON INDIAN 1 1 4.49 YES SIGNET + MUCINNEGATIVE POSITIVE POSITIVE POSITIVE T2N1 T2 N1
15 37 MALE MARRIED UNSKILLEDINDIAN 1 3 28.7 NO SIGNET RING CELL CARCINOMANEGATIVE POSITIVE POSITIVE POSITIVE T3N1 T3 N1
16 60 MALE MARRIED UNSKILLEDINDIAN 1 1 4.39 NO SIGNET RING CELL CARCINOMANOT ASSESSED. . . T3N0 T3 N0
17 43 MALE MARRIED UNSKILLEDINDIAN 1 0 1.14 YES SIGNET + MUCINNEGATIVE POSITIVE POSITIVE POSITIVE T3cN1 T3 N1
18 27 MALE MARRIED UNSKILLEDINDIAN 1 3 10.8 NO SIGNET RING CELL CARCINOMANEGATIVE POSITIVE POSITIVE POSITIVE T3N2 T3 N2
19 18 MALE UNMARRIEDUNSKILLEDINDIAN 1 1 5.74 YES SIGNET RING CELL CARCINOMANEGATIVE POSITIVE POSITIVE POSITIVE T3N2 T3 N2
20 30 MALE MARRIED UNSKILLEDNON INDIAN 1 4 6.92 YES SIGNET RING CELL CARCINOMANEGATIVE POSITIVE POSITIVE POSITIVE T3N2 T3 N2
21 25 FEMALE MARRIED UNSKILLEDINDIAN 1 6 250 NO SIGNET + MUCINNOT ASSESSED. . . T3N2 T3 N2
22 32 FEMALE MARRIED UNSKILLEDINDIAN 1 3 3.51 NO SIGNET RING CELL CARCINOMANEGATIVE POSITIVE POSITIVE POSITIVE T4aN2 T4 N2
CRM RT DOSE FRACTIONSCAPECITABINERT TECHNIQUETRG MRI POST RT CEASURGERY PATHOLOGICAL STAGINGypN ypT PATHOLOGICAL TRG POST OPMARGIN
INVOLVED 5040 25 NO IMRT absence of regressive changes (no response)608 INOPERABLE. . . . .
INVOLVED 5040 28 YES 2D . 2.71 INOPERABLE. . . . .
INVOLVED 5040 28 YES 2D absence of regressive changes (no response)2.74 INOPERABLE. . . . .
INVOLVED 5040 28 YES 2D residual cancer cells outgrowing the fibrosis (minimal response)3.04 INOPERABLE. . . . .
UNINVOLVED 5040 28 YES IMRT residual cancer cells outgrowing the fibrosis (minimal response)5.22 AR T2N0 N0 T2 NEAR COMPLETE RESPONSENEGATIVE
INVOLVED 5040 28 YES 2D residual cancer cells outgrowing the fibrosis (minimal response)3.11 EXENTERATION3N1b N1 T3 MINIMAL RESPONSE NEGATIVE
INVOLVED 5040 28 YES 2D residual cancer cells outgrowing the fibrosis (minimal response)1.78 HARTMANN'ST3N0 N0 T3 NO RESPONSE NEGATIVE
INVOLVED 5040 28 YES 2D residual cancer cells outgrowing the fibrosis (minimal response)1.36 APE T3N0 N0 T3 NO RESPONSE NEGATIVE
INVOLVED 5040 28 YES 2D residual cancer cells outgrowing the fibrosis (minimal response)1.9 AR T0N0 N0 T0 COMPLETE RESPONSENEGATIVE
INVOLVED 5040 28 YES 3D predominant fibrosis but increase in the number of cancer cells (moderate2.58 AR T0N0 N0 T0 COMPLETE RESPONSENEGATIVE
INVOLVED 5040 28 YES 3D residual cancer cells outgrowing the fibrosis (minimal response)0.74 AR T3N0 N0 T3 NEAR COMPLETE RESPONSENEGATIVE
INVOLVED 5040 28 YES 2D residual cancer cells outgrowing the fibrosis (minimal response)4.59 APE T2N0 N0 T2 NEAR COMPLETE RESPONSENEGATIVE
INVOLVED 5040 28 YES 2D residual cancer cells outgrowing the fibrosis (minimal response)1.2 AR T0N0 N0 T0 COMPLETE RESPONSENEGATIVE
INVOLVED 5040 28 YES 2D absence of regressive changes (no response)3.99 APE T0N0 N0 T0 COMPLETE RESPONSENEGATIVE
INVOLVED 5040 28 YES 2D predominant fibrosis but increase in the number of cancer cells (moderate9.28 APE T4aN2a N2 T4 NO RESPONSE POSITIVE
THREATENED 5040 28 YES 2D rare residual tumour cells scattered throughout the fibrosis (near complete1.81 APE T1N0 N0 T1 NEAR COMPLETE RESPONSENEGATIVE
INVOLVED 5040 28 YES 2D absence of regressive changes (no response)1.83 INOPERABLE. . . . .
INVOLVED 5040 28 YES 2D residual cancer cells outgrowing the fibrosis (minimal response)3.71 APE T0N0 N0 T0 COMPLETE RESPONSENEGATIVE
INVOLVED 5040 28 YES 2D residual cancer cells outgrowing the fibrosis (minimal response)3.2 INOPERABLE. . . . .
INVOLVED 5040 28 YES 2D predominant fibrosis but increase in the number of cancer cells (moderate19.1 INOPERABLE. . . . .
. 5040 28 YES 2D residual cancer cells outgrowing the fibrosis (minimal response)11.6 HARTMANN'ST3N2a N2 T3 NO RESPONSE NEGATIVE
INVOLVED 5040 28 YES 3D absence of regressive changes (no response)1.15 APE T0N0 N0 T0 COMPLETE RESPONSENEGATIVE
